0HMP.L - Bellerophon Therapeutics, Inc.

LSE - LSE Delayed price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.90
52-week change 3404.06%
S&P500 52-week change 32.54%
52-week high 312.35
52-week low 30.00
50-day moving average 37.54
200-day moving average 36.42

Share statistics

Avg vol (3-month) 34.15k
Avg vol (10-day) 3721
Shares outstanding 5N/A
Implied shares outstanding 6N/A
Float 87.05M
% held by insiders 14.11%
% held by institutions 144.43%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 20.066667:1
Last split date 310 Feb 2020

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)31 Mar 2023


Profit margin -201.56%
Operating margin (ttm)-270.71%

Management effectiveness

Return on assets (ttm)-50.61%
Return on equity (ttm)-84.92%

Income statement

Revenue (ttm)5.64M
Revenue per share (ttm)0.58
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -15.22M
Net income avi to common (ttm)-11.37M
Diluted EPS (ttm)-1.88
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)15.17M
Total cash per share (mrq)1.45
Total debt (mrq)8k
Total debt/equity (mrq)0.08
Current ratio (mrq)2.94
Book value per share (mrq)1.01

Cash flow statement

Operating cash flow (ttm)-9.77M
Levered free cash flow (ttm)-8.17M